-Klaus Podar Researcher Activity Profile

Research Author Detailed Information 

Klaus Podar Publication Rate By Year

Klaus Podar has published 2 paper(s) in 2006, 11 paper(s) in 2007, 4 paper(s) in 2008, for a total of 17 research publications in total.

Klaus K Podar Author Information

LAST NAME: podar

FIRST NAME: klaus

INITIALS: K

AFFILIATION:

Papers

Klaus Podar's Publication Record

1. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. klaus.podar@dfci.harvard.edu
2. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
3. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
4. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
5. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
6. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. yu-tzu_tai@dfci.harvard.edu
7. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
8. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
9. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Year Published: 2007
Dana-Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
10. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
11. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
12. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
13. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
14. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
15. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
16. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. dharminder_chauhan@dfci.harvard.edu
17. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.